Izalontamab Brengitecan in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations Outside of Classical EGFR Mutations: A Phase Ib Study.

Journal:
Journal of Clinical Oncology
Published:
DOI:
10.1200/jco-25-01929
Affiliations:
8
Authors:
16
Go to article
Institutions Authors Share
State Key Laboratory of Oncology in South China, SYSUCC, China
8.000000
 0.50
Sun Yat-sen University Cancer Center (SYSUCC), SYSU, China
2.000000
 0.13
Biokin Pharma, China
2.000000
 0.13
SystImmune, United States of America (USA)
1.000000
 0.06
Hospital and Cancer Center, CQU, China
1.000000
 0.06
West China School of Medicine/West China Hospital of Sichuan University (WCSM/WCH), SCU, China
1.000000
 0.06
Fujian Cancer Hospital, China
1.000000
 0.06
Interested in Oncology and Carcinogenesis?